Market Outlook

By 2035, the U.S. Diabetes Care Devices Market is expected to reach approximately USD 44.85 billion, growing at a CAGR of 9.65% during the forecast period 2026–2035. The market was valued at USD 17.85 billion in 2025, with historical analysis from 2021 to 2024. Values in this report are expressed in USD billions.

The U.S. diabetes care devices industry is entering a new growth cycle in which continuous glucose monitoring, automated insulin delivery, tubeless pumps, connected insulin pens, implantable sensors, and digital coaching platforms are progressively replacing fragmented manual workflows. The commercial opportunity is supported by a national diabetes population that now exceeds 40 million people, a diagnosed population above 31 million, and a prediabetes pool above 115 million adults. The disease burden is clinically persistent, economically material, and increasingly managed outside the hospital, creating recurring demand for sensors, transmitters, infusion sets, pods, pen needles, lancets, test strips, smart dosing accessories, and subscription-based data services.

Diabetes generated an estimated USD 412.9 billion in total U.S. economic cost in 2022, including USD 306.6 billion in direct medical expenditures and USD 106.3 billion in indirect cost. People with diagnosed diabetes incur medical spending approximately 2.6 times higher than expected in the absence of the disease. This cost structure is important for device manufacturers because payers and providers increasingly evaluate technology through its ability to improve time in range, reduce severe hypoglycemia, prevent diabetic ketoacidosis, support medication titration, lower avoidable emergency utilization, and delay expensive complications involving the kidney, cardiovascular system, retina, and lower extremities.

The historical market expanded from USD 12.35 billion in 2021 to USD 16.31 billion in 2024 as prescription CGM adoption accelerated, pharmacy access improved, automated insulin delivery systems gained clinical acceptance, and supply revenue expanded with a larger installed base. In 2025, the market reached USD 17.85 billion. Growth was led by CGM, which became the largest product pool by value, while insulin pump systems, wearable patches, and device-linked software outpaced conventional blood glucose meters and test strips. The forecast assumes continued premium growth in sensor-based monitoring and automated delivery, partly offset by price compression in mature self-monitoring products.

The market estimate covers devices and directly associated recurring supplies used for glucose measurement, insulin administration, automated dosing, and connected diabetes management. It includes blood glucose monitoring systems, continuous and flash glucose monitoring, insulin pumps, patch pumps, infusion sets, insulin pens, smart pen attachments, syringes, pen needles, lancets, software-enabled controllers, and device-specific data services. It excludes insulin and other pharmaceutical products, general-purpose hospital infusion pumps, routine central-laboratory analyzers, and wellness applications that do not materially support diabetes-device use. This scope is designed to reflect the addressable revenue pool evaluated by medtech manufacturers, investors, distributors, health systems, pharmacy channels, and payer stakeholders.

Introduction

According to the U.S. Diabetes Care Devices Market Report, the industry is shaped by a combination of high chronic disease prevalence, long treatment duration, recurring consumable economics, expanding reimbursement, rapid sensor innovation, and growing patient preference for less burdensome care. Diabetes management is unusually device-intensive because treatment decisions depend on frequent glucose information, reliable insulin administration, behavioral feedback, and longitudinal data review. The result is a market in which clinical outcomes, user experience, payer coverage, supply continuity, and digital interoperability influence adoption as strongly as technical specifications.

The U.S. market is not a single homogeneous device category. It combines high-volume commodity supplies with premium wearable systems and algorithm-controlled platforms. Blood glucose meters, test strips, lancets, syringes, and pen needles provide a broad baseline of demand across insulin-treated and non-insulin-treated populations. CGM sensors, transmitters, receivers, insulin pumps, disposable pods, infusion sets, and automated insulin delivery controllers create higher recurring revenue per patient. Connected pens, dose-capture accessories, clinician dashboards, and remote monitoring services add a software and data layer that can increase retention and strengthen manufacturer relationships with providers and payers.

The care pathway is also more decentralized than most medical device markets. Hospitals and endocrinology centers influence initiation, education, and complex treatment decisions, but most device use occurs in the home. Retail pharmacies, specialty pharmacies, durable medical equipment suppliers, direct manufacturer channels, telehealth programs, and integrated delivery networks all participate in fulfillment. This fragmented channel structure raises the strategic importance of benefits verification, prior authorization support, patient onboarding, refill management, adherence outreach, and customer service. A clinically strong product can underperform commercially when distribution friction, training burden, or supply interruptions are not controlled.

U.S. procurement economics differ by product class. Hospitals and clinics evaluate point-of-care meters, inpatient CGM pilots, professional CGM programs, pump training infrastructure, and data platforms through enterprise contracts and clinical governance. Home-use CGM and pumps are more often influenced by payer formularies, pharmacy benefit design, DME rules, patient cost sharing, and prescriber workflow. For manufacturers, success therefore requires both clinical selling and access execution. The value proposition must address accuracy and outcomes for clinicians, affordability and simplicity for patients, documentation and coding for suppliers, and total medical cost for payers.

From 2026 to 2035, the defining strategic shift will be from device ownership to continuously managed diabetes ecosystems. The strongest platforms will connect sensing, dosing, education, remote review, and population analytics. Manufacturers that can reduce setup time, extend sensor wear, automate insulin adjustment, simplify refills, support multiple payer channels, and demonstrate real-world outcomes will be positioned to capture a larger share of the patient lifetime value. Companies dependent on standalone hardware without a recurring consumable or software relationship will face greater pricing pressure and lower switching barriers.

Key Market Drivers: What’s Fueling the U.S. Diabetes Care Devices Market Boom?

The first major driver is the scale and persistence of the U.S. diabetes burden. More than 40 million Americans live with diabetes, and the national prevalence of total diabetes among adults reached approximately 13.5% in 2021–2023. Type 2 diabetes represents roughly 90% to 95% of cases, while type 1 diabetes creates substantially higher device intensity per patient because continuous monitoring and insulin delivery are central to daily survival. The combination of new diagnoses, longer life expectancy, obesity, aging, and earlier detection supports a steadily expanding installed base for monitoring and delivery devices.

A second driver is reimbursement expansion for CGM. Medicare policy now supports coverage for beneficiaries who are insulin-treated or have documented problematic hypoglycemia, removing the former requirement for multiple daily insulin administrations. This materially enlarges the addressable population among older adults and basal-insulin users. Coverage is still documentation-sensitive, and continued eligibility requires periodic clinician review, but the policy direction favors broader use of sensor-based monitoring. Commercial plans and Medicaid programs are also expanding access, although state-level criteria and formulary preferences remain uneven.

A third driver is the recurring economics of disposable sensors, pods, infusion sets, pen needles, and test strips. Once a patient is successfully initiated on a platform, the manufacturer can generate predictable replenishment revenue. Disposable sensor and supply sales account for the overwhelming majority of revenue for major CGM companies, demonstrating the importance of installed-base growth and retention. This model supports continuous investment in manufacturing scale, consumer support, and software, but it also increases sensitivity to product reliability, fulfillment performance, payer renewals, and competitive switching programs.

A fourth driver is the rapid adoption of automated insulin delivery. Closed-loop and hybrid closed-loop systems combine a CGM, insulin pump, and dosing algorithm to adjust insulin based on real-time glucose trends. The FDA clearance of an automated insulin dosing system for adults with type 2 diabetes in 2024 expanded the category beyond its historical type 1 focus. This creates a significantly larger long-term opportunity among insulin-intensive type 2 patients, particularly when systems become easier to prescribe, train, and support in primary care and community endocrinology settings.

A fifth driver is consumerization. Over-the-counter CGM created a new route to market for adults who do not use insulin, including people using oral medicines and consumers seeking metabolic feedback. Pharmacy availability, smartphone-first interfaces, simplified packaging, and direct digital onboarding can reduce the friction associated with traditional DME distribution. The commercial upside is substantial, but manufacturers must manage expectations carefully because consumer wellness use differs from treatment-grade use. Clear labeling, data interpretation, customer education, and responsible claims will be essential to durable adoption.

A sixth driver is the need to improve clinical workflow economics. Endocrinology capacity is limited, primary care practices manage most type 2 diabetes, and clinicians face increasing data volume from CGM and connected devices. Platforms that prioritize exceptions, summarize time in range, identify hypoglycemia, support remote review, and document treatment changes can reduce manual analysis. Health systems are more likely to standardize devices when data can flow into existing clinical systems and when training, technical support, and population management are included in the contract.

A seventh driver is the high cost of preventable complications. Diabetes was listed in more than 8 million adult hospital discharges in 2021, and diabetes-related hospitalizations involving lower-extremity amputation doubled between 2009 and 2019. These outcomes strengthen payer interest in technologies that detect deterioration earlier and support better glycemic control. Devices do not eliminate the broader social and clinical determinants of diabetes, but evidence of reduced severe events, improved adherence, and more timely therapeutic adjustment can justify premium reimbursement and value-based contracting.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. diabetes care devices market is increasingly directed toward reducing cognitive burden rather than merely increasing measurement frequency. The next competitive frontier is a system that requires fewer insertions, fewer calibrations, fewer manual calculations, fewer device interactions, and less time spent resolving coverage or supply issues. Product development is therefore converging around longer wear duration, smaller form factors, factory calibration, smartphone control, interoperable components, predictive alerts, automated dosing, and simplified training.

CGM innovation remains the most powerful technology cycle. Sensor duration is extending from 10 to 15 days for mainstream wearable systems, while implantable platforms can provide up to one year of use. Manufacturers are improving startup performance, adhesive reliability, alarm logic, data continuity, and integration with pumps and digital health applications. Accuracy remains essential, but commercial differentiation increasingly depends on the complete use experience, including insertion, warm-up, phone compatibility, sharing, replacement policy, and access to support.

Automated insulin delivery algorithms are becoming more adaptive and interoperable. Systems now adjust basal insulin, deliver correction doses, and respond to glucose trends at frequent intervals. The market is moving away from closed proprietary stacks toward selective partnerships between pump and CGM manufacturers. This gives patients and clinicians more choice, but it also creates technical and regulatory complexity. Cybersecurity, software validation, update governance, and accountability across multiple manufacturers will become more important as connected systems manage a greater share of insulin dosing decisions.

Insulin pump design is shifting toward discretion, wearability, and reduced setup burden. Tubeless pumps have expanded the addressable market among users who reject conventional tubing, while compact app-controlled pumps seek to preserve automated delivery with less visible hardware. Disposable patch systems for mealtime insulin target type 2 patients who need a simpler alternative to multiple injections but may not require a full-featured pump. The winning products will match clinical intensity with the lowest practical training and maintenance requirement.

Connected multiple-daily-injection technology is becoming a strategic middle ground between conventional pens and pumps. Smart pens and dose-capture attachments can record insulin timing, estimate active insulin, combine dose history with CGM data, and provide correction guidance. This segment is relevant because many insulin users are unwilling or unable to adopt pump therapy. Manufacturers that integrate connected pens with pharmacy workflows and widely used CGM systems can access a larger population without the higher capital and training burden associated with pumps.

Professional and remote CGM models are also evolving. Short-term professional sensor use can help clinicians identify glycemic patterns, evaluate medication response, and initiate a longer-term treatment plan. Remote monitoring platforms can then support ongoing review, especially for high-risk patients, pregnancy, insulin initiation, or recent discharge. The economic challenge is to fit data review into reimbursable and scalable workflows. Device companies are responding with automated reports, population dashboards, triage rules, and integration services that reduce the time required per patient.

Manufacturers are raising the evidence standard as the category broadens. U.S. buyers increasingly expect randomized evidence, real-world utilization data, subgroup outcomes, human-factors testing, cybersecurity controls, and health-economic analysis. The FDA’s active oversight of recalls and software corrections reinforces the importance of post-market surveillance and rapid communication. Over the forecast period, quality systems and supply resilience will become competitive assets, particularly for products that patients depend on continuously and that directly influence insulin dosing.

Segmentation Insights

The U.S. Diabetes Care Devices Market is segmented on the basis of product category, diabetes type, end user, distribution channel, technology type, and region.

By Product Category

• Continuous glucose monitoring systems represent the largest and fastest-expanding product category. The segment includes disposable sensors, transmitters, receivers, applicators, professional CGM, implantable CGM, and over-the-counter biosensors. CGM accounted for an estimated USD 8.55 billion of U.S. market revenue in 2025. Growth is supported by broader Medicare eligibility, commercial pharmacy coverage, longer wear duration, automated insulin delivery integration, and entry into non-insulin-treated type 2 diabetes. The principal commercial risks are pricing pressure, sensor recalls, smartphone compatibility, and payer concentration.
• Blood glucose monitoring systems remain a large installed-base category despite gradual substitution by CGM. This segment includes meters, test strips, control solutions, lancets, and lancing devices. Demand is sustained by non-CGM users, occasional confirmatory testing, inpatient and institutional use, and patients who face coverage or affordability barriers. Test strips remain the primary recurring revenue source, but competitive intensity and private-label availability constrain growth. Manufacturers are focusing on low sample volume, connectivity, accuracy, and simplified retail access.
• Insulin pumps and automated delivery systems form the highest-value insulin administration category. Products include durable pumps, tubeless patch pumps, disposable pods, infusion sets, reservoirs, controllers, and algorithm-enabled systems. The segment benefits from a growing installed base, recurring supply revenue, and wider CGM integration. Adoption is strongest in type 1 diabetes but is moving into insulin-intensive type 2 diabetes. Commercial success depends on training capacity, payer authorization, device reliability, upgrade programs, and the ability to retain users through multi-year warranty cycles.
• Insulin pens, syringes, pen needles, and injection accessories provide stable high-volume demand. Although these products are mature, they remain essential because multiple daily injections continue to be the dominant insulin delivery method in the U.S. Pen needles and syringes offer recurring consumption, while reusable connected pens and dose-capture devices create a higher-value innovation layer. Growth is strongest where manufacturers can reduce injection burden, support adherence, and link dosing data to CGM or clinician platforms.
• Smart diabetes accessories and data-management products include connected pen caps, dose calculators, device-specific mobile applications, cloud portals, remote monitoring dashboards, and integrated patient support tools. This category is smaller in direct revenue but has outsized strategic importance because it influences retention, clinical workflow, and platform differentiation. Standalone software faces reimbursement challenges, while device-linked software can strengthen the economics of hardware and consumables. The most valuable products are those that convert raw glucose and dosing data into actionable clinical decisions.

By Diabetes Type

• Type 1 diabetes represents the most device-intensive patient segment. Although the population is much smaller than type 2 diabetes, a high proportion of patients require lifelong insulin and frequent glucose monitoring. CGM penetration is highest in this group, and automated insulin delivery is increasingly becoming the preferred technology pathway for eligible users. Pediatric adoption, parental data sharing, school-time management, and transition to adult care are important submarkets. Revenue per patient is high because sensors, pump supplies, and software relationships recur continuously.
• Insulin-treated type 2 diabetes is the largest incremental growth opportunity through 2035. The segment includes people using basal insulin, multiple daily injections, concentrated insulin, and pump therapy. Broader CGM coverage has reduced the historical dependence on fingerstick testing, while automated dosing and patch delivery can address treatment complexity. Adoption will depend on primary care simplicity, pharmacy access, affordability, and evidence that technology improves outcomes in populations with varied digital literacy and comorbidity burden.
• Non-insulin-treated type 2 diabetes is becoming commercially relevant as CGM moves beyond intensive insulin management. Prescription CGM can support medication adjustment and behavioral change, while over-the-counter systems create a consumer-paid pathway. The segment is very large but has lower expected annual device spending per user. Retention will depend on whether users receive understandable insights rather than raw data. Partnerships with clinicians, employers, digital health programs, and metabolic-care platforms can improve the value proposition.
• Gestational diabetes is a smaller but clinically important segment characterized by temporary, high-frequency monitoring needs. Treatment decisions can change rapidly during pregnancy, and maternal-fetal risk increases when glucose remains uncontrolled. Blood glucose meters remain widely used, while CGM is gaining interest for selected patients and complex pregnancies. Hospital systems and maternal-fetal medicine practices prioritize accuracy, patient education, rapid supply access, and secure data sharing. The episodic nature of use limits lifetime revenue, but the need for timely management supports premium service models.
• Other and secondary diabetes includes monogenic diabetes, pancreatic disease-related diabetes, steroid-induced hyperglycemia, and treatment-associated diabetes. These groups are smaller and clinically heterogeneous, but they can require intensive monitoring and individualized insulin administration. Device choice is influenced by duration, treatment intensity, dexterity, cognitive ability, and concurrent disease. Manufacturers generally address these patients through broad indications rather than dedicated products, yet specialty centers value flexible platforms that can be configured for complex cases.

By End User

• Homecare settings dominate the U.S. diabetes care devices market because most glucose monitoring and insulin delivery occur in daily life rather than in formal care facilities. Patients and caregivers perform sensor insertion, fingerstick testing, injections, pod changes, infusion-set replacement, and device troubleshooting. Products that minimize steps, reduce pain, and provide reliable support have a major commercial advantage. Home use also makes packaging, refill continuity, shipping, smartphone compatibility, and customer-service quality central components of clinical performance.
• Hospitals and health systems are important purchasers of point-of-care meters, inpatient glucose testing supplies, insulin delivery accessories, professional CGM services, and enterprise data platforms. Inpatient adoption of personal CGM is increasing selectively, but hospitals remain cautious because of workflow integration, confirmatory testing protocols, cybersecurity, infection control, and responsibility for clinical decisions. Large systems can influence outpatient device standardization through discharge pathways, employee health plans, formularies, and affiliated physician networks.
• Endocrinology clinics, diabetes centers, and physician practices are the primary clinical gatekeepers for advanced devices. These providers evaluate eligibility, prescribe technology, document medical necessity, review data, and manage training. Limited specialist capacity can slow market growth when setup is complex. Manufacturers that provide certified educators, virtual onboarding, automated documentation, and efficient data review can expand prescriber willingness. Primary care enablement will be particularly important for type 2 diabetes growth because most patients are managed outside endocrinology.
• Retail pharmacies, specialty pharmacies, and DME suppliers function as both distribution and service end users. They verify benefits, process claims, obtain prior authorization, coordinate refills, and communicate with patients. Channel performance can determine whether a prescription converts into an active user. Pharmacy benefit access can accelerate adoption, while DME remains important for Medicare and pump supplies. Suppliers increasingly prefer products with predictable documentation, low return rates, strong reimbursement support, and automated replenishment systems.
• Telehealth, employer health, and digital chronic-care providers represent a fast-growing end-user class. These organizations combine connected devices with coaching, medication management, and population analytics. Their purchasing decisions are based on engagement, measurable outcomes, member retention, and total medical cost. They can expand access among people without regular endocrinology care, but they also pressure device prices through large contracts. Successful manufacturers will provide interoperable data, flexible fulfillment, and clear evidence that the device improves program performance.

By Distribution Channel

• Durable medical equipment suppliers remain a core channel for Medicare-covered CGM, insulin pumps, and recurring supplies. The channel is documentation-intensive and requires accurate coding, eligibility verification, proof of delivery, and periodic clinical follow-up. Supplier economics depend on reimbursement levels, inventory turns, denial rates, and service workload. Manufacturers that simplify claims support and automate resupply can gain preferred status. DME will remain important even as more CGM volume shifts to pharmacy because pumps and certain Medicare pathways continue to rely on it.
• Retail and specialty pharmacy channels are gaining share because they provide familiar access, faster prescription conversion, and integration with pharmacy benefits. Pharmacy distribution can reduce the administrative burden associated with DME, especially for commercially insured users. It also improves visibility at the point of prescription and can support same-day initiation in some markets. However, formulary placement, rebate structures, wholesaler relationships, and pharmacy inventory management can create margin pressure. Manufacturers need strong payer contracting and demand forecasting to succeed.
• Direct manufacturer channels are strategically important for insulin pumps, implantable sensors, upgrades, replacement programs, and subscription-style CGM services. Direct engagement gives companies greater control over education, benefits investigation, onboarding, technical support, and retention. It also creates high service costs and requires sophisticated call-center and digital operations. The best-performing direct models coordinate with prescribers and payers without transferring excessive administrative burden to the patient.
• Institutional and group purchasing channels cover hospitals, integrated delivery networks, clinics, government facilities, and large employer or health-plan programs. These buyers negotiate on volume, service levels, data integration, and measurable outcomes. Price is important, but continuity of supply and standardization can be equally decisive. Enterprise agreements can create durable share, yet they often require implementation support, cybersecurity review, training, and performance guarantees. Broad-portfolio companies can bundle meters, supplies, CGM, and data services to improve contract leverage.
• E-commerce and over-the-counter channels are emerging as a distinct growth route for nonprescription CGM, meters, strips, lancets, and connected accessories. This channel can reach consumers who are outside traditional reimbursement pathways and supports rapid product comparison. It also increases price transparency and exposes brands to reviews, return behavior, and digital acquisition costs. Trust, labeling clarity, data privacy, and customer education will determine whether OTC CGM develops into a durable metabolic-health category or remains episodic self-experimentation.

By Technology Type

• Conventional invasive and needle-based technologies include fingerstick meters, lancets, syringes, pen needles, infusion sets, and reusable pens. These products remain foundational because they are affordable, widely reimbursed, and familiar to clinicians and patients. Growth is modest, but demand is durable. Innovation focuses on smaller blood volume, less painful sampling, safety-engineered needles, ergonomic design, and connected meters. Cost efficiency and manufacturing scale are the primary competitive advantages.
• Minimally invasive wearable technologies include disposable CGM sensors, tubeless pumps, patch delivery systems, and compact infusion devices. This is the largest growth pool because wearables reduce manual testing and can integrate monitoring with therapy. Adhesive performance, skin tolerance, water resistance, size, insertion comfort, and wear duration strongly influence retention. The economics are attractive because most products require recurring replacement, but quality problems can quickly affect a large installed base.
• Implantable technologies currently center on long-duration CGM. A one-year implanted sensor can reduce the frequency of self-insertion and may appeal to users who value long wear and consistent placement. Adoption is constrained by the need for trained insertion and removal, clinic capacity, and reimbursement coordination. The segment will remain smaller than disposable CGM, but it provides differentiation and may expand if procedure burden, calibration requirements, and integration options continue to improve.
• Integrated automated insulin delivery technologies combine interoperable CGM, pump hardware, infusion or pod supplies, control algorithms, and mobile or dedicated controllers. They command high value because they automate a clinically consequential workflow. The segment is expected to grow at a double-digit rate through 2035 as eligibility expands and systems become easier to use. Competitive differentiation will depend on time-in-range performance, meal-handling flexibility, alarm burden, device choice, pediatric indications, and reliability.
• Software-enabled and AI-assisted technologies form the intelligence layer across the market. Algorithms summarize glucose patterns, predict risk, recommend or automate dosing, identify patients needing outreach, and support remote monitoring. Software alone captures a smaller share of revenue than sensors and supplies, but it increasingly determines which hardware platforms win. Key procurement issues include clinical validation, interoperability, privacy, cybersecurity, update control, liability, and the ability to integrate into clinician workflow without adding alert fatigue.

Regional Insights: Where the Market is Growing Fastest

The U.S. Diabetes Care Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs according to population scale, diabetes prevalence, age, rural access, payer mix, Medicaid policy, pharmacy infrastructure, endocrinologist density, health-system concentration, and technology adoption. The South represents the largest market because it combines a large population with a high diabetes burden. The West is expected to post the fastest growth, supported by California’s scale and early adoption of connected care. The Northeast remains premium and clinically influential, while the Midwest provides a stable base with important state-led coverage expansion.

South

The South is the dominant regional market, accounting for an estimated USD 6.78 billion in 2025 and projected to reach approximately USD 16.92 billion by 2035. The region includes Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia, and the District of Columbia. Its leadership is supported by large absolute patient populations, elevated diagnosed diabetes prevalence in many states, high obesity burden, rapid population growth, and substantial Medicare and Medicaid exposure.

Texas and Florida are the two most important commercial markets in the region. Texas has nearly 3 million adults with diagnosed diabetes, representing approximately 12% of the adult population, and generates an estimated USD 34.3 billion in annual diabetes-related direct and indirect cost. The state supports high device volume through large metropolitan markets in Houston, Dallas–Fort Worth, San Antonio, and Austin, but access is uneven in rural and border communities. Florida has more than 2 million adults with diagnosed diabetes and a large Medicare-age population, creating strong demand for CGM, insulin delivery, and home-based monitoring.

Georgia, North Carolina, Tennessee, and Virginia are major growth states because of population expansion, large health systems, and a mix of urban specialty care and rural disease burden. Tennessee has more than 800,000 adults with diagnosed diabetes and a prevalence near 13%. North Carolina is strategically important because recent surveillance found rural diabetes prevalence as high as 21.3% in the state sample. These markets require two commercial models: premium automated systems in metropolitan endocrinology networks and simplified, remotely supported devices in rural communities.

Alabama, Mississippi, Louisiana, Kentucky, Arkansas, Oklahoma, South Carolina, and West Virginia have some of the country’s highest diabetes and obesity burdens. These states offer substantial need-based demand for meters, strips, injection supplies, and CGM, but affordability, clinician shortages, transportation, and broadband access can limit adoption of premium platforms. West Virginia recorded one of the highest urban diabetes prevalence estimates at 15.5% in a recent rural–urban analysis. Medicaid coverage policy and manufacturer assistance programs are therefore especially important to market penetration.

Maryland and the District of Columbia have smaller populations but high-value care ecosystems, major academic centers, federal health institutions, and dense payer networks. Virginia combines affluent metropolitan markets with rural areas where diabetes access gaps remain significant. Across the South, the strongest growth will come from Medicare-covered CGM, pharmacy conversion, type 2 automated insulin delivery, and health-system programs that extend specialist oversight through remote monitoring. Manufacturers must build multilingual support, rural fulfillment capability, and strong Medicaid access strategies.

The South will remain the largest market through 2035, but growth will not be uniform. Texas, Florida, Georgia, and North Carolina will generate the greatest absolute revenue expansion, while high-prevalence states can deliver faster percentage growth when coverage improves. Companies that rely only on high-income self-pay or specialist channels will underpenetrate the region. The most defensible strategies combine national payer contracting with local provider education, pharmacy availability, community partnerships, and robust patient onboarding.

West

The West represented an estimated USD 4.37 billion in 2025 and is expected to reach approximately USD 11.72 billion by 2035, making it the fastest-growing region. It includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. The region combines the country’s largest state market, rapidly growing Sun Belt populations, major integrated delivery networks, technology-oriented consumers, and a strong digital health and medtech ecosystem.

California is the largest state-level market in the West and one of the largest nationally. Approximately 3.5 million adults in the state have diagnosed diabetes, or about 10.5% of the adult population, and direct medical expenses associated with diagnosed diabetes were estimated at more than USD 34 billion in 2022. California supports early adoption of CGM, automated insulin delivery, virtual care, and direct-to-consumer metabolic technology. Its commercial potential is offset by payer complexity, socioeconomic disparity, and the need to serve multiple languages and care settings.

Arizona and Nevada are high-growth markets because of population migration, aging, and expanding hospital networks. Arizona has approximately 668,000 adults with diagnosed diabetes. Phoenix, Tucson, Las Vegas, and Reno provide concentrated pharmacy and specialty-care opportunities, while remote communities require telehealth and mail-order fulfillment. New Mexico has a smaller population but a high burden of diabetes among rural, Hispanic, and Native American communities, making culturally competent education and reliable supply access essential.

Washington, Oregon, Colorado, and Utah are important early-adoption markets. Washington has nearly 596,000 adults with diagnosed diabetes, and Colorado has approximately 404,000, with diagnosed prevalence near 8%, below many Southern states. Lower prevalence does not reduce commercial attractiveness because these states have strong employer coverage, integrated health systems, digitally engaged populations, and advanced care-management infrastructure. Oregon is notable for pronounced rural–urban disparity, reinforcing the value of connected monitoring and remote support.

Idaho, Montana, Wyoming, Alaska, and Hawaii are smaller but operationally distinctive markets. Long travel distances, limited specialist density, and shipping complexity increase the value of durable devices, virtual onboarding, and dependable resupply. Alaska and Hawaii also require careful logistics and inventory planning. In these states, a manufacturer’s distribution capability and technical support network can matter more than marginal product differentiation. Partnerships with regional health systems, tribal health organizations, and government programs can improve access.

The West will gain market share through 2035 as diabetes care becomes more consumer-oriented, software-enabled, and integrated with virtual care. California will remain the regional anchor, while Arizona, Nevada, Washington, Colorado, and Utah deliver strong percentage growth. The region is particularly attractive for over-the-counter CGM, connected injection systems, employer-sponsored metabolic programs, and platform partnerships. Manufacturers should expect sophisticated privacy, interoperability, and user-experience requirements from both consumers and enterprise buyers.

Northeast

The Northeast accounted for an estimated USD 3.75 billion in 2025 and is projected to reach approximately USD 9.17 billion by 2035. The region includes Connecticut, Delaware, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. It is a mature but high-value market characterized by dense specialist networks, leading academic medical centers, strong commercial insurance, large integrated health systems, and rigorous evidence-based procurement.

New York is the largest state market in the region, with approximately 1.7 million adults living with diagnosed diabetes in recent 2025 estimates. New York City and surrounding metropolitan areas support substantial CGM, pump, and connected-care demand, while upstate communities face rural access and affordability constraints. The state’s elimination of insulin copays in state-regulated plans reflects a broader policy environment focused on affordability, although device coverage remains dependent on benefit design and plan criteria.

Pennsylvania and New Jersey provide large, diversified markets with strong pharmacy networks and major health systems. New Jersey has approximately 774,000 adults with diagnosed diabetes. Pennsylvania combines high-volume metropolitan care in Philadelphia and Pittsburgh with older and rural populations that can benefit from Medicare CGM expansion. Delaware is smaller but commercially connected to the Mid-Atlantic corridor. These states are attractive for enterprise contracts that combine device access, population management, and remote monitoring.

Massachusetts is disproportionately influential because of its academic centers, biotechnology ecosystem, payer sophistication, and concentration of diabetes research. Approximately 560,000 adults in Massachusetts have diagnosed diabetes, with prevalence near 8.5%. Connecticut and Rhode Island share similar characteristics: mature coverage, high clinician density, and strong interest in outcomes evidence. These markets are receptive to advanced devices but demand high-quality implementation, interoperability, cybersecurity review, and clinical support.

Maine, New Hampshire, and Vermont are smaller markets with older populations and substantial rural geography. The device opportunity is strongest in home-based CGM, mail-order supplies, and remote data review that reduces travel to specialty centers. Reliable cellular or broadband connectivity cannot be assumed in every community, so offline functionality, durable receivers, and telephone support remain relevant. Regional providers may favor products that can be standardized across multi-state health systems and supported with minimal staff burden.

The Northeast will grow slightly below the national rate because it is more mature and has slower population expansion. Nevertheless, it will remain one of the most profitable regions on a per-patient basis. Early adoption at academic centers can influence national clinical practice, and large payer-provider organizations can generate meaningful contract volume. Market leaders will be those that support rigorous evidence review, integrate data into established systems, and offer clear economic value beyond device accuracy alone.

Midwest

The Midwest represented an estimated USD 2.95 billion in 2025 and is expected to reach approximately USD 7.04 billion by 2035. The region includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. Demand is supported by large community hospital networks, established endocrinology programs, significant rural populations, and a durable base of insulin-treated patients. The region is also important for manufacturing, distribution, and payer innovation.

Illinois, Ohio, Michigan, and Minnesota are the principal state markets. Illinois has approximately 1.2 million adults with diagnosed diabetes, or about 10.8% of its adult population. Chicago supports advanced technology adoption, while downstate communities create demand for remote support and pharmacy-based access. Illinois legislation expanding CGM access for Medicaid beneficiaries strengthens the state’s growth outlook. Ohio and Michigan offer large patient pools and broad health-system networks, while Minnesota contributes a sophisticated medtech and payer ecosystem.

Indiana, Missouri, and Wisconsin provide substantial mid-sized markets. Indiana has nearly 700,000 adults with diagnosed diabetes and prevalence near 11.5%. These states combine metropolitan specialty centers with rural areas where primary care carries most of the diabetes-management workload. Devices that can be initiated without lengthy in-person training and reviewed remotely are particularly attractive. Employer-sponsored coverage and regional Blues plans can materially influence access and vendor share.

Iowa, Kansas, Nebraska, North Dakota, and South Dakota are smaller in absolute revenue but strategically important for rural diabetes management. Long travel distances and limited endocrinologist supply increase the value of telehealth, connected meters, CGM sharing, and automated resupply. A recent multistate analysis found rural diabetes prevalence averaging 14.3% compared with 11.2% in urban areas. Manufacturers that provide reliable receivers, phone-based support, and simplified benefit navigation can outperform purely app-centric models.

The Midwest is expected to grow at a steady rate through 2035, with upside from Medicaid coverage expansion, Medicare CGM, integrated delivery networks, and adoption of automated insulin delivery beyond major academic centers. The region is price-sensitive but values service reliability and long-term vendor relationships. Companies that demonstrate lower administrative burden, stable supply, and strong educator support can defend share even when competing products offer similar core clinical performance.

Key Market Players

The U.S. Diabetes Care Devices Competitive Landscape is concentrated in CGM and automated insulin delivery but remains fragmented across blood glucose monitoring, injection supplies, smart pens, software, and distribution. Abbott and Dexcom lead the sensor-based monitoring market, while MiniMed, Insulet, Tandem Diabetes Care, Beta Bionics, and emerging pump developers compete in automated delivery. Mature categories such as meters, test strips, syringes, and pen needles include established global manufacturers and lower-cost specialists.

Competition is increasingly ecosystem-based. Manufacturers seek to control or influence the sensor, dosing device, algorithm, mobile application, cloud platform, refill relationship, and patient-support experience. Interoperability partnerships can accelerate market access but also redistribute bargaining power across the ecosystem. Broad platforms can bundle products and data, while specialized companies can gain share by solving a specific burden such as tubeless delivery, one-year sensing, connected injections, or simplified type 2 insulin administration.

Some of the key players in the U.S. Diabetes Care Devices industry are

• Abbott Laboratories,
• DexCom, Inc.,
• MiniMed Group, Inc.,
• Insulet Corporation,
• Tandem Diabetes Care, Inc.,
• embecta Corp.,
• Roche Diabetes Care,
• LifeScan, Inc.,
• Ascensia Diabetes Care Holdings AG,
• Senseonics Holdings, Inc.,
• Beta Bionics, Inc.,
• Sequel Med Tech, LLC,
• Ypsomed Holding AG,
• Becton, Dickinson and Company,
• Novo Nordisk A/S,
• Eli Lilly and Company,
• CeQur SA,
• DarioHealth Corp.,
• Teladoc Health, Inc. (Livongo),
• Glooko, Inc.,
• AgaMatrix, Inc.,
• Trividia Health, Inc.,
• Nipro Diagnostics, Inc.,
• iHealth Labs Inc.,
• Prodigy Diabetes Care, LLC.

Abbott and Dexcom have the strongest scale advantages in CGM because of their installed bases, recurring sensor revenue, manufacturing investment, brand recognition, and integration relationships. MiniMed, Insulet, and Tandem compete through automated insulin delivery platforms, while Beta Bionics and Sequel Med Tech add algorithm and form-factor innovation. Senseonics differentiates through implantable CGM. embecta, BD, Roche, LifeScan, Ascensia, Trividia, Nipro, AgaMatrix, and Prodigy remain important in injection and self-monitoring categories where affordability, retail access, and supply reliability are decisive.

Market share through 2035 will be influenced by FDA clearances, sensor performance, product quality, payer formulary position, pharmacy access, DME execution, interoperability, manufacturing yield, customer support, and the ability to expand into type 2 diabetes. Companies that demonstrate improved time in range, lower severe-event risk, high retention, and reduced administrative burden will be better positioned to sustain premium pricing. Recalls, cybersecurity events, supply disruptions, and poor onboarding can rapidly weaken share because users depend on these products continuously.

Recent Developments

Recent developments in the U.S. Diabetes Care Devices Market show a decisive expansion beyond traditional prescription monitoring. In March 2024, the FDA cleared the first over-the-counter continuous glucose monitor, creating a direct-access category for adults who do not use insulin. Additional OTC systems followed, including products designed for people with type 2 diabetes and consumers seeking metabolic information. This development widened the addressable market but also increased the importance of labeling, education, responsible data interpretation, and consumer support.

Automated insulin delivery entered a new patient segment in August 2024 when the FDA cleared the first automated dosing device for adults with type 2 diabetes. This was strategically important because automated systems had previously been concentrated in type 1 diabetes. The clearance supports a longer-term shift toward technology-assisted insulin management for millions of adults with type 2 diabetes, although large-scale adoption will require simplified prescribing, primary care education, payer access, and evidence in diverse real-world populations.

Long-duration sensing advanced in September 2024 with clearance of a CGM system designed for up to one year of use. Implantable sensing offers a differentiated alternative to repeatedly inserted disposable sensors and can reduce insertion frequency. The model requires a trained provider for placement and removal, creating a distinct service network and reimbursement pathway. The development demonstrates that the U.S. market can support multiple wear models rather than converging on a single sensor format.

Sensor duration and interoperability continued to improve during 2025 and 2026. Fifteen-day wearable sensors expanded, and pump manufacturers pursued broader compatibility with leading CGM platforms. The separation and public listing of MiniMed in March 2026 also changed the competitive structure by creating a more focused standalone diabetes technology company with an integrated portfolio spanning pumps, sensors, algorithms, consumables, and applications. This is likely to intensify investment and partnership activity across automated delivery.

Regulatory oversight remains an important market factor. Device recalls and software corrections involving glucose sensors and insulin pumps during 2024–2026 reinforced the need for manufacturing control, transparent communication, and rapid replacement capability. Because CGM and pump users depend on uninterrupted performance, post-market quality can influence brand trust and payer preference as much as product launch speed. Manufacturers are increasing investments in traceability, remote software remediation, customer notification, and redundant supply planning.

Reimbursement policy continued to support category expansion. Medicare criteria recognize insulin-treated beneficiaries and certain people with problematic hypoglycemia, while continued coverage requires documented follow-up. State Medicaid programs are progressively expanding CGM access, although eligibility remains uneven. These changes favor companies with strong market-access teams and channel partners that can manage documentation. Over the next several years, coverage breadth and administrative simplicity will be among the strongest determinants of state-level adoption.

Conclusion

The U.S. Diabetes Care Devices Market Size & Share is positioned for sustained expansion from USD 17.85 billion in 2025 to USD 44.85 billion by 2035, supported by a 9.65% CAGR during the forecast period. The market’s long-term strength is grounded in the scale of diabetes and prediabetes, the recurring nature of monitoring and delivery supplies, broader CGM reimbursement, the expansion of automated insulin delivery, and the shift of chronic disease management into connected homecare.

The most attractive growth opportunities will come from prescription and over-the-counter CGM, type 2 automated insulin delivery, tubeless and compact pumps, longer-duration sensors, connected multiple-daily-injection systems, pharmacy distribution, and workflow software that helps clinicians manage larger populations. Conventional meters, strips, needles, and syringes will remain important, but their value growth will be constrained by substitution and price competition. Premium expansion will increasingly depend on demonstrable reduction in treatment burden and total medical cost.

Regional opportunity will be led by the South because of population scale and disease burden, followed by the West’s technology adoption and population growth, the Northeast’s high-value specialist and payer infrastructure, and the Midwest’s stable patient base and emerging coverage reforms. Texas, California, Florida, New York, Illinois, Pennsylvania, Georgia, North Carolina, Ohio, Michigan, New Jersey, Arizona, Washington, Massachusetts, Tennessee, and Indiana will be especially important for manufacturers, suppliers, and investors.

For clients evaluating this market, the critical question is not simply whether device demand will grow. The more important questions are which patient groups will convert from fingerstick testing to CGM, how rapidly automated delivery will penetrate type 2 diabetes, which channel will control the refill relationship, and which manufacturers can maintain quality while scaling recurring production. Companies that combine clinically differentiated hardware, access execution, interoperable data, reliable fulfillment, and evidence-based economic value will define the next decade of the U.S. diabetes care devices industry.

TABLE OF CONTENT

1. U.S. Diabetes Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.2.1. Included Device Categories
1.2.2. Excluded Products and Market Boundaries
1.2.3. Historical Period, 2021–2024
1.2.4. Base Year, 2025
1.2.5. Forecast Period, 2026–2035
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Glucose Monitoring Device Manufacturers
1.6.2. Insulin Delivery and Automated Insulin Delivery Manufacturers
1.6.3. Sensor, Microfluidics, Semiconductor and Component Suppliers
1.6.4. Contract Development and Manufacturing Organizations
1.6.5. Hospitals, Health Systems and Diabetes Specialty Centers
1.6.6. Retail Pharmacies, Durable Medical Equipment Suppliers and Distributors
1.6.7. Payers, Pharmacy Benefit Managers, Employers and Government Programs
1.6.8. Endocrinologists, Primary Care Providers, Diabetes Educators and Patients
What this section provides: This section defines the U.S. diabetes care devices market boundary, study scope, methodology, assumptions, time horizon, and stakeholder ecosystem so clients understand how market estimates and forecasts are developed and validated.

2. U.S. Diabetes Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.7.1. Continuous Glucose Monitoring Expansion
2.7.2. Automated Insulin Delivery Adoption
2.7.3. Type 2 Diabetes Device Penetration
2.7.4. Over-the-Counter and Consumer-Accessible Glucose Sensing
2.7.5. Connected Insulin Delivery and Remote Patient Management
What this section provides: This section gives decision-makers a concise view of market size, growth direction, leading device categories, competitive intensity, reimbursement catalysts, and the highest-priority commercial opportunity areas.

3. U.S. Diabetes Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Large and Rising U.S. Diabetes Population
3.1.2. Shift from Finger-Stick Testing to Continuous Glucose Monitoring
3.1.3. Expansion of Medicare and Commercial CGM Coverage
3.1.4. Growth of Insulin Pump and Automated Insulin Delivery Adoption
3.1.5. Increasing Use of Diabetes Devices in Type 2 Diabetes
3.1.6. Growth in Remote Monitoring, Tele-endocrinology and Connected Care
3.1.7. Demand for Improved Time-in-Range and Hypoglycemia Reduction
3.2. Restraints and Their Impact Analysis
3.2.1. High Out-of-Pocket Costs and Coverage Variability
3.2.2. Complex Pharmacy and Durable Medical Equipment Benefit Pathways
3.2.3. Device Training, Adherence and Wearability Barriers
3.2.4. Product Recalls, Sensor Accuracy Concerns and Cybersecurity Risk
3.2.5. Data Integration Burden for Clinical Teams
3.3. Opportunities and Their Impact Analysis
3.3.1. CGM Expansion Across Non-Insulin-Treated Type 2 Diabetes
3.3.2. Over-the-Counter CGM and Metabolic Health Applications
3.3.3. Interoperable and Fully Automated Insulin Delivery Systems
3.3.4. Smart Insulin Pens, Connected Caps and Dose-Adherence Platforms
3.3.5. Remote Patient Monitoring and Value-Based Diabetes Management
3.3.6. Longer-Wear, Implantable and Minimally Invasive Sensors
3.4. Challenges and Their Impact Analysis
3.4.1. Health Equity and Digital Access Gaps
3.4.2. Algorithm Interoperability and Device Compatibility
3.4.3. Patient Data Privacy and Cybersecurity Compliance
3.4.4. Supply Chain Continuity for Sensors, Infusion Sets and Electronics
3.4.5. Demonstrating Durable Clinical and Economic Outcomes
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Diabetes Clinical Workflow Economics Analysis
3.7. Payer, Pharmacy Benefit and Health-System Procurement Behavior Analysis
3.8. Patient Lifetime Value and Recurring Consumables Economics
What this section provides: This section explains the epidemiological, clinical, reimbursement, behavioral, technological, and commercial forces shaping diabetes-device demand, helping clients evaluate growth potential, adoption barriers, recurring-revenue economics, and execution risk.

4. U.S. Diabetes Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.3.1. CGM Sensor and Receiver Pricing Trends
4.3.2. Insulin Pump and Consumables Pricing Trends
4.3.3. Blood Glucose Meter, Strip and Lancet Pricing Trends
4.3.4. Connected Device and Software Subscription Pricing Trends
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Diabetes Care
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. 510(k), De Novo and Premarket Approval Pathways
4.7.2. Integrated Continuous Glucose Monitoring Requirements
4.7.3. Alternate Controller-Enabled Pump and Interoperability Requirements
4.7.4. Human Factors, Software and Cybersecurity Expectations
4.8. CMS and Private Payer Reimbursement & Coverage Landscape
4.8.1. Medicare CGM Coverage
4.8.2. Insulin Pump and Supply Coverage
4.8.3. Pharmacy Benefit versus DME Benefit Coverage
4.8.4. Medicaid and Commercial Plan Variation
4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Initiatives and Diabetes Prevention Programs
4.11. Impact of Escalating Geopolitical Tensions
4.12. Payer Formulary, Health-System Value Analysis and Coverage Decision Framework
What this section provides: This section gives clients a complete view of the external market environment, including regulation, reimbursement, pricing, supply chain, interoperability, technology adoption, public policy, and payer or provider purchasing dynamics.

5. U.S. Diabetes Care Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Continuous Glucose Monitoring Systems
5.1.2.1. Real-Time Continuous Glucose Monitoring Systems
5.1.2.2. Intermittently Scanned Continuous Glucose Monitoring Systems
5.1.2.3. Professional Continuous Glucose Monitoring Systems
5.1.2.4. Implantable Continuous Glucose Monitoring Systems
5.1.2.5. CGM Sensors
5.1.2.6. CGM Transmitters
5.1.2.7. CGM Receivers and Smartphone Display Interfaces
5.1.3. Self-Monitoring Blood Glucose Systems
5.1.3.1. Blood Glucose Meters
5.1.3.2. Blood Glucose Test Strips
5.1.3.3. Lancets and Lancing Devices
5.1.3.4. Control Solutions and Calibration Accessories
5.1.4. Insulin Delivery Devices
5.1.4.1. Tubed Insulin Pumps
5.1.4.2. Patch Insulin Pumps
5.1.4.3. Reusable Insulin Pens
5.1.4.4. Disposable Prefilled Insulin Pens
5.1.4.5. Smart Insulin Pens and Connected Caps
5.1.4.6. Insulin Syringes
5.1.4.7. Pen Needles and Safety Needles
5.1.4.8. Infusion Sets, Cartridges and Reservoirs
5.1.5. Automated Insulin Delivery Systems
5.1.5.1. Hybrid Closed-Loop Systems
5.1.5.2. Advanced Hybrid Closed-Loop Systems
5.1.5.3. Interoperable Pump-CGM-Algorithm Platforms
5.1.5.4. Bihormonal and Fully Closed-Loop Systems
5.1.6. Digital and Connected Diabetes Care Devices
5.1.6.1. Connected Blood Glucose Meters
5.1.6.2. Dose Calculation and Insulin Decision-Support Devices
5.1.6.3. Remote Monitoring Gateways and Data Hubs
5.1.6.4. Device-Linked Diabetes Management Software
5.1.6.5. Patient and Clinician Data-Sharing Platforms
What this section provides: This section identifies which diabetes care device categories and subcategories are expected to generate the largest revenue contribution, strongest recurring consumables demand, and highest growth through 2035.

6. U.S. Diabetes Care Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Type 1 Diabetes Management
6.1.2.1. Glucose Monitoring
6.1.2.2. Insulin Pump Therapy
6.1.2.3. Automated Insulin Delivery
6.1.2.4. Hypoglycemia Prevention and Remote Monitoring
6.1.3. Insulin-Treated Type 2 Diabetes Management
6.1.3.1. Basal-Bolus Insulin Management
6.1.3.2. CGM-Guided Dose Adjustment
6.1.3.3. Smart Pen and Connected Injection Management
6.1.3.4. Pump and Patch-Pump Therapy
6.1.4. Non-Insulin-Treated Type 2 Diabetes Management
6.1.4.1. Structured Blood Glucose Monitoring
6.1.4.2. Episodic and Professional CGM
6.1.4.3. Lifestyle and Medication Response Monitoring
6.1.4.4. Over-the-Counter Glucose Sensing
6.1.5. Gestational Diabetes Management
6.1.5.1. Home Blood Glucose Monitoring
6.1.5.2. CGM-Supported Pregnancy Management
6.1.5.3. Insulin Delivery and Dose Management
6.1.5.4. Postpartum Monitoring
6.1.6. Inpatient and Acute-Care Glycemic Management
6.1.6.1. Critical Care Glucose Monitoring
6.1.6.2. Non-Critical Inpatient Glucose Monitoring
6.1.6.3. Perioperative Glycemic Management
6.1.6.4. Discharge Transition and Remote Follow-Up
What this section provides: This section helps clients understand demand by diabetes population and clinical use case, including where monitoring intensity, insulin delivery needs, reimbursement support, and technology adoption are strongest.

7. U.S. Diabetes Care Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Health Systems
7.1.2.1. Academic Medical Centers
7.1.2.2. Community Hospitals
7.1.2.3. Integrated Delivery Networks
7.1.2.4. Inpatient Diabetes Management Programs
7.1.3. Endocrinology and Diabetes Specialty Centers
7.1.3.1. Endocrinology Group Practices
7.1.3.2. Certified Diabetes Care and Education Programs
7.1.3.3. Pediatric Diabetes Centers
7.1.3.4. Maternal-Fetal Medicine and Gestational Diabetes Clinics
7.1.4. Primary Care, Retail Clinics and Community Health Centers
7.1.4.1. Primary Care Practices
7.1.4.2. Federally Qualified Health Centers
7.1.4.3. Retail Health Clinics
7.1.4.4. Rural and Safety-Net Providers
7.1.5. Homecare Patients and Caregivers
7.1.5.1. Adults with Type 1 Diabetes
7.1.5.2. Adults with Type 2 Diabetes
7.1.5.3. Pediatric and Adolescent Patients
7.1.5.4. Older Adults and Medicare Beneficiaries
7.1.6. Telehealth and Remote Diabetes Management Providers
7.1.6.1. Virtual Endocrinology Providers
7.1.6.2. Remote Patient Monitoring Programs
7.1.6.3. Employer-Sponsored Diabetes Management Programs
7.1.6.4. Payer-Sponsored Digital Diabetes Programs
What this section provides: This section explains which care settings and customer groups are expected to drive device prescribing, purchasing, patient onboarding, recurring supply utilization, and remote-monitoring demand.

8. U.S. Diabetes Care Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Standalone and Intermittent Monitoring Technologies
8.1.2.1. Conventional Blood Glucose Monitoring
8.1.2.2. Professional and Episodic Monitoring
8.1.2.3. Hospital Point-of-Care Monitoring
8.1.3. Connected and Bluetooth-Enabled Technologies
8.1.3.1. Connected Glucose Meters
8.1.3.2. Connected Insulin Pens and Caps
8.1.3.3. Cloud-Connected Pump Platforms
8.1.3.4. Remote Data-Sharing Ecosystems
8.1.4. Wearable and Minimally Invasive Technologies
8.1.4.1. Transcutaneous CGM Sensors
8.1.4.2. Implantable CGM Sensors
8.1.4.3. Patch Pumps and Wearable Insulin Delivery
8.1.4.4. Emerging Non-Invasive Glucose-Sensing Technologies
8.1.5. Automated and Closed-Loop Technologies
8.1.5.1. Predictive Low-Glucose Suspend
8.1.5.2. Hybrid Closed-Loop
8.1.5.3. Advanced Hybrid Closed-Loop
8.1.5.4. Fully Automated and Bihormonal Systems
8.1.6. Software-Enabled and AI-Assisted Technologies
8.1.6.1. Insulin Dosing Algorithms
8.1.6.2. Pattern Recognition and Glycemic Risk Prediction
8.1.6.3. Clinician Decision-Support Platforms
8.1.6.4. Population Health and Remote Triage Analytics
What this section provides: This section evaluates the technology platforms reshaping diabetes care, including connected devices, wearable sensors, automated insulin delivery, interoperability, and AI-assisted monitoring or dosing workflows.

9. U.S. Diabetes Care Devices Market – By Procurement & Distribution Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement & Distribution Channel, 2025 & 2035 (%)
9.1.2. Retail Pharmacy Channel
9.1.2.1. National Chain Pharmacies
9.1.2.2. Independent and Regional Pharmacies
9.1.2.3. Specialty Pharmacies
9.1.2.4. Health-System Outpatient Pharmacies
9.1.3. Durable Medical Equipment and Mail-Order Channel
9.1.3.1. National DME Suppliers
9.1.3.2. Regional DME Suppliers
9.1.3.3. Medicare Mail-Order Fulfillment
9.1.3.4. Recurring Sensor, Infusion Set and Supply Replenishment
9.1.4. Direct Institutional Procurement
9.1.4.1. Hospital and Health-System Contracts
9.1.4.2. Integrated Delivery Network Standardization
9.1.4.3. Group Purchasing Organization Contracts
9.1.4.4. Clinic and Diabetes Center Procurement
9.1.5. Online, E-Commerce and Direct-to-Consumer Channel
9.1.5.1. Manufacturer Direct Fulfillment
9.1.5.2. Online Pharmacy Platforms
9.1.5.3. Consumer Health E-Commerce
9.1.5.4. Subscription-Based Replenishment Programs
9.1.6. Payer, Employer and Population-Health Contracting
9.1.6.1. Commercial Payer Preferred-Device Contracts
9.1.6.2. Pharmacy Benefit Manager Formulary Agreements
9.1.6.3. Employer-Sponsored Diabetes Programs
9.1.6.4. Value-Based and Outcomes-Linked Contracts
What this section provides: This section helps clients understand how diabetes devices and recurring supplies reach U.S. patients, including pharmacy, DME, institutional, e-commerce, payer, employer, and value-based contracting pathways.

10. U.S. Diabetes Care Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diabetes Prevalence, Insulin Use and Device Adoption Analysis
10.1.4. Regional Endocrinology Capacity, Retail Pharmacy and DME Infrastructure Analysis
10.1.5. Regional Medicare, Medicaid and Commercial Coverage Dynamics
10.1.6. Regional Health Equity, Rural Access and Remote Monitoring Analysis
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Diabetes Care Device Key Manufacturers, Payer Networks and Distribution Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Diabetes Care Device Key Manufacturers, Payer Networks and Distribution Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Diabetes Care Device Key Manufacturers, Payer Networks and Distribution Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Diabetes Care Device Key Manufacturers, Payer Networks and Distribution Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement & Distribution Channel, 2021–2035 (US$ Billion)
What this section provides: This section delivers detailed regional and state-level analysis, helping clients identify priority U.S. geographies, diabetes-burden concentrations, CGM and pump adoption hotspots, payer-access differences, distribution infrastructure, rural-access gaps, and state-level commercial opportunities.

11. U.S. Diabetes Care Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.1.1. Market Share by Glucose Monitoring Portfolio
11.1.2. Market Share by Insulin Delivery Portfolio
11.1.3. Market Share by Connected Diabetes Ecosystem
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Company Profiles
11.3.1. Abbott Laboratories
11.3.2. Dexcom, Inc.
11.3.3. Medtronic plc
11.3.4. Insulet Corporation
11.3.5. Tandem Diabetes Care, Inc.
11.3.6. Roche Diabetes Care
11.3.7. LifeScan, Inc.
11.3.8. Ascensia Diabetes Care
11.3.9. embecta Corp.
11.3.10. Becton, Dickinson and Company
11.3.11. Senseonics Holdings, Inc.
11.3.12. Beta Bionics, Inc.
11.3.13. Sequel Med Tech, LLC
11.3.14. Ypsomed Holding AG
11.3.15. CeQur SA
11.3.16. Novo Nordisk A/S
11.3.17. Eli Lilly and Company
11.3.18. Sanofi
11.3.19. Glooko, Inc.
11.3.20. DarioHealth Corp.
11.3.21. Teladoc Health, Inc. (Livongo)
11.3.22. AgaMatrix, Inc.
11.3.23. Nova Biomedical
11.3.24. Trividia Health, Inc.
11.3.25. Biolinq Incorporated
Note: Each company profile will include company overview, U.S. diabetes-device portfolio, installed user base and recurring-revenue model, commercial strategy, financial positioning, clinical evidence, regulatory updates, partnerships, distribution relationships, interoperability strategy, and recent developments.
What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, installed-base economics, innovation direction, channel strategy, and strategic intelligence on leading and emerging diabetes care device companies.

12. U.S. Diabetes Care Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Longer-Wear and Implantable Continuous Glucose Monitoring
12.2.2. Over-the-Counter CGM and Consumer Metabolic Monitoring
12.2.3. Fully Automated and Bihormonal Insulin Delivery
12.2.4. Interoperable Pump-CGM-Algorithm Ecosystems
12.2.5. AI-Assisted Insulin Dosing and Glycemic Risk Prediction
12.2.6. Smart Insulin Pens and Connected Injection Management
12.2.7. Emerging Non-Invasive Glucose-Sensing Platforms
12.3. Emerging Business Trends
12.3.1. Recurring Sensor and Consumables Revenue Models
12.3.2. Pharmacy-First Device Access
12.3.3. Payer Preferred-Device and Outcomes-Based Contracting
12.3.4. Consumerization of Diabetes Technology
12.3.5. Platform Integration and Data Ecosystem Competition
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Adoption Curve, 2026–2035
What this section provides: This section prepares clients for future technology shifts, reimbursement evolution, market-structure changes, investment opportunities, and plausible adoption scenarios across glucose monitoring, insulin delivery, connected care, and emerging sensing technologies through 2035.

13. U.S. Diabetes Care Devices Market: Strategic Recommendations

13.1. Recommendations for Diabetes Device Manufacturers
13.2. Recommendations for Hospitals, Health Systems and Diabetes Centers
13.3. Recommendations for Payers, Pharmacy Benefit Managers and Employers
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Retail Pharmacies, DME Suppliers and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.7.1. Pharmacy versus DME Channel Strategy
13.7.2. Provider Education and Patient Onboarding
13.7.3. Payer Evidence and Health-Economic Positioning
13.7.4. State-Level Market Prioritization
13.8. Product Positioning and Portfolio Expansion Guidance
13.9. Partnership, Interoperability and Ecosystem Strategy
13.10. Commercialization Roadmap, 2026–2035
What this section provides: This section converts market intelligence into actionable strategy for portfolio planning, payer access, channel expansion, patient onboarding, product positioning, investment decisions, partnership development, and competitive differentiation.

14. U.S. Diabetes Care Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Medical and Clinical Decision Disclaimer
14.7. Regulatory and Reimbursement Change Disclaimer
What this section provides: This section clarifies the report’s scope, limitations, legal boundaries, data-use terms, clinical-use restrictions, regulatory uncertainty, reimbursement variability, and forecasting assumptions.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Diabetes Care Devices Market: Market Definition and Scope
TABLE 3: U.S. Diabetes Care Devices Market: Included Device Categories and Market Boundaries
TABLE 4: U.S. Diabetes Care Devices Market: Research Methodology Framework
TABLE 5: U.S. Diabetes Care Devices Market: Key Assumptions
TABLE 6: U.S. Diabetes Care Devices Market: Market Ecosystem and Stakeholder Analysis
TABLE 7: U.S. Diabetes Care Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Diabetes Care Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Diabetes Care Devices Market: Market Attractiveness Index
TABLE 10: U.S. Diabetes Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Diabetes Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Diabetes Care Devices Market: High-Growth Opportunity Areas, 2026–2035
TABLE 13: U.S. Diabetes Care Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. Diabetes Care Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. Diabetes Care Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. Diabetes Care Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. Diabetes Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Diabetes Care Devices Market: Diabetes Clinical Workflow Economics Matrix
TABLE 19: U.S. Diabetes Care Devices Market: Payer, Pharmacy Benefit and Health-System Procurement Behavior Matrix
TABLE 20: U.S. Diabetes Care Devices Market: Patient Lifetime Value and Recurring Consumables Economics
TABLE 21: U.S. Diabetes Care Devices Market: PESTEL Analysis
TABLE 22: U.S. Diabetes Care Devices Market: Porter’s Five Forces Analysis
TABLE 23: U.S. Diabetes Care Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 24: U.S. Diabetes Care Devices Market: Value Chain Analysis
TABLE 25: U.S. Diabetes Care Devices Market: Supply Chain Analysis
TABLE 26: U.S. Diabetes Care Devices Market: Digitalization and Connected Diabetes Care Impact
TABLE 27: U.S. Diabetes Care Devices Market: Application & Innovation Landscape
TABLE 28: U.S. Diabetes Care Devices Market: FDA Regulatory Framework Analysis
TABLE 29: U.S. Diabetes Care Devices Market: CMS and Private Payer Reimbursement & Coverage Landscape
TABLE 30: U.S. Diabetes Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 31: U.S. Diabetes Care Devices Market: Government Initiatives and Diabetes Prevention Programs
TABLE 32: U.S. Diabetes Care Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 33: U.S. Diabetes Care Devices Market: Payer Formulary, Health-System Value Analysis and Coverage Decision Framework
TABLE 34: U.S. Diabetes Care Devices Market: Product Category Snapshot, 2025
TABLE 35: Segment Dashboard; Definition and Scope, by Product Category
TABLE 36: U.S. Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 37: U.S. Diabetes Care Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 38: U.S. Diabetes Care Devices Market: Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 39: U.S. Diabetes Care Devices Market: Self-Monitoring Blood Glucose Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 40: U.S. Diabetes Care Devices Market: Insulin Delivery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 41: U.S. Diabetes Care Devices Market: Automated Insulin Delivery Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: U.S. Diabetes Care Devices Market: Digital and Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Diabetes Care Devices Market: Application Snapshot, 2025
TABLE 44: Segment Dashboard; Definition and Scope, by Application
TABLE 45: U.S. Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 46: U.S. Diabetes Care Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 47: U.S. Diabetes Care Devices Market: Type 1 Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Diabetes Care Devices Market: Insulin-Treated Type 2 Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Diabetes Care Devices Market: Non-Insulin-Treated Type 2 Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Diabetes Care Devices Market: Gestational Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Diabetes Care Devices Market: Inpatient and Acute-Care Glycemic Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Diabetes Care Devices Market: End User Snapshot, 2025
TABLE 53: Segment Dashboard; Definition and Scope, by End User
TABLE 54: U.S. Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 55: U.S. Diabetes Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 56: U.S. Diabetes Care Devices Market: Hospitals and Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Diabetes Care Devices Market: Endocrinology and Diabetes Specialty Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Diabetes Care Devices Market: Primary Care, Retail Clinics and Community Health Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Diabetes Care Devices Market: Homecare Patients and Caregivers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Diabetes Care Devices Market: Telehealth and Remote Diabetes Management Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Diabetes Care Devices Market: Technology Type Snapshot, 2025
TABLE 62: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 63: U.S. Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 64: U.S. Diabetes Care Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 65: U.S. Diabetes Care Devices Market: Standalone and Intermittent Monitoring Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Diabetes Care Devices Market: Connected and Bluetooth-Enabled Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Diabetes Care Devices Market: Wearable and Minimally Invasive Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Diabetes Care Devices Market: Automated and Closed-Loop Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Diabetes Care Devices Market: Software-Enabled and AI-Assisted Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Diabetes Care Devices Market: Procurement & Distribution Channel Snapshot, 2025
TABLE 71: Segment Dashboard; Definition and Scope, by Procurement & Distribution Channel
TABLE 72: U.S. Diabetes Care Devices Market, by Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 73: U.S. Diabetes Care Devices Market: Segment Share Analysis, by Procurement & Distribution Channel, 2025 & 2035 (%)
TABLE 74: U.S. Diabetes Care Devices Market: Retail Pharmacy Channel Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Diabetes Care Devices Market: Durable Medical Equipment and Mail-Order Channel Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Diabetes Care Devices Market: Direct Institutional Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Diabetes Care Devices Market: Online, E-Commerce and Direct-to-Consumer Channel Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Diabetes Care Devices Market: Payer, Employer and Population-Health Contracting Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Diabetes Care Devices Market: Regional Snapshot, 2025
TABLE 80: Segment Dashboard; Definition and Scope, by Region
TABLE 81: U.S. Diabetes Care Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 82: U.S. Diabetes Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 83: West Region U.S. Diabetes Care Devices Market: Regional Overview and Trends
TABLE 84: West Region U.S. Diabetes Care Devices Market: Key Manufacturers, Payer Networks and Distribution Ecosystem
TABLE 85: West Region U.S. Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 86: West Region U.S. Diabetes Care Devices Market, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 87: California Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 88: Washington Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 89: Arizona Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 90: Colorado Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 91: Oregon Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 92: Utah Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 93: Nevada Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 94: New Mexico Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 95: Idaho Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 96: Montana Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 97: Wyoming Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 98: Alaska Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 99: Hawaii Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 100: Northeast Region U.S. Diabetes Care Devices Market: Regional Overview and Trends
TABLE 101: Northeast Region U.S. Diabetes Care Devices Market: Key Manufacturers, Payer Networks and Distribution Ecosystem
TABLE 102: Northeast Region U.S. Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 103: Northeast Region U.S. Diabetes Care Devices Market, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 104: New York Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 105: Massachusetts Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 106: New Jersey Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 107: Pennsylvania Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 108: Connecticut Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 109: Maine Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 110: Vermont Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 111: New Hampshire Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 112: Rhode Island Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 113: Delaware Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 114: South Region U.S. Diabetes Care Devices Market: Regional Overview and Trends
TABLE 115: South Region U.S. Diabetes Care Devices Market: Key Manufacturers, Payer Networks and Distribution Ecosystem
TABLE 116: South Region U.S. Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 117: South Region U.S. Diabetes Care Devices Market, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 118: Texas Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 119: Florida Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 120: Georgia Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 121: North Carolina Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 122: Tennessee Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 123: South Carolina Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 124: Alabama Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 125: Mississippi Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 126: Louisiana Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 127: Arkansas Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 128: Kentucky Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 129: Oklahoma Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 130: Virginia Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 131: Maryland Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 132: West Virginia Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 133: Midwest Region U.S. Diabetes Care Devices Market: Regional Overview and Trends
TABLE 134: Midwest Region U.S. Diabetes Care Devices Market: Key Manufacturers, Payer Networks and Distribution Ecosystem
TABLE 135: Midwest Region U.S. Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 136: Midwest Region U.S. Diabetes Care Devices Market, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 137: Illinois Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 138: Ohio Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 139: Michigan Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 140: Minnesota Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 141: Indiana Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 142: Wisconsin Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 143: Missouri Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 144: Iowa Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 145: Kansas Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 146: Nebraska Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 147: North Dakota Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 148: South Dakota Diabetes Care Devices Market: Market Size and Forecast, by Product Category, Application, End User, Technology Type and Procurement & Distribution Channel, 2021–2035 (US$ Billion)
TABLE 149: U.S. Diabetes Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 150: U.S. Diabetes Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 151: U.S. Diabetes Care Devices Market: Market Share by Glucose Monitoring Portfolio, 2025
TABLE 152: U.S. Diabetes Care Devices Market: Market Share by Insulin Delivery Portfolio, 2025
TABLE 153: U.S. Diabetes Care Devices Market: Market Share by Connected Diabetes Ecosystem, 2025
TABLE 154: U.S. Diabetes Care Devices Market: Company Positioning Matrix
TABLE 155: U.S. Diabetes Care Devices Market: Product Portfolio and Recurring-Revenue Benchmarking
TABLE 156: U.S. Diabetes Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 157: Abbott Laboratories: Company Profile
TABLE 158: Dexcom, Inc.: Company Profile
TABLE 159: Medtronic plc: Company Profile
TABLE 160: Insulet Corporation: Company Profile
TABLE 161: Tandem Diabetes Care, Inc.: Company Profile
TABLE 162: Roche Diabetes Care: Company Profile
TABLE 163: LifeScan, Inc.: Company Profile
TABLE 164: Ascensia Diabetes Care: Company Profile
TABLE 165: embecta Corp.: Company Profile
TABLE 166: Becton, Dickinson and Company: Company Profile
TABLE 167: Senseonics Holdings, Inc.: Company Profile
TABLE 168: Beta Bionics, Inc.: Company Profile
TABLE 169: Sequel Med Tech, LLC: Company Profile
TABLE 170: Ypsomed Holding AG: Company Profile
TABLE 171: CeQur SA: Company Profile
TABLE 172: Novo Nordisk A/S: Company Profile
TABLE 173: Eli Lilly and Company: Company Profile
TABLE 174: Sanofi: Company Profile
TABLE 175: Glooko, Inc.: Company Profile
TABLE 176: DarioHealth Corp.: Company Profile
TABLE 177: Teladoc Health, Inc. (Livongo): Company Profile
TABLE 178: AgaMatrix, Inc.: Company Profile
TABLE 179: Nova Biomedical: Company Profile
TABLE 180: Trividia Health, Inc.: Company Profile
TABLE 181: Biolinq Incorporated: Company Profile
TABLE 182: U.S. Diabetes Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 183: U.S. Diabetes Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 184: U.S. Diabetes Care Devices Market: Emerging Business Trends
TABLE 185: U.S. Diabetes Care Devices Market: Business Opportunities for Startups and Existing Players
TABLE 186: U.S. Diabetes Care Devices Market: Investment Prioritization Matrix
TABLE 187: U.S. Diabetes Care Devices Market: Technology Adoption Curve, 2026–2035
TABLE 188: U.S. Diabetes Care Devices Market: Strategic Recommendations for Diabetes Device Manufacturers
TABLE 189: U.S. Diabetes Care Devices Market: Strategic Recommendations for Hospitals, Health Systems and Diabetes Centers
TABLE 190: U.S. Diabetes Care Devices Market: Strategic Recommendations for Payers, Pharmacy Benefit Managers and Employers
TABLE 191: U.S. Diabetes Care Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 192: U.S. Diabetes Care Devices Market: Strategic Recommendations for Retail Pharmacies, DME Suppliers and Channel Partners
TABLE 193: U.S. Diabetes Care Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 194: U.S. Diabetes Care Devices Market: Go-to-Market Strategy Considerations
TABLE 195: U.S. Diabetes Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 196: U.S. Diabetes Care Devices Market: Partnership, Interoperability and Ecosystem Strategy
TABLE 197: U.S. Diabetes Care Devices Market: Commercialization Roadmap, 2026–2035
TABLE 198: U.S. Diabetes Care Devices Market: Scope Limitation
TABLE 199: U.S. Diabetes Care Devices Market: Data Use Limitation
TABLE 200: U.S. Diabetes Care Devices Market: Forecasting Limitation
TABLE 201: U.S. Diabetes Care Devices Market: Legal Disclaimer
TABLE 202: U.S. Diabetes Care Devices Market: Third-Party Data Disclaimer
TABLE 203: U.S. Diabetes Care Devices Market: Medical and Clinical Decision Disclaimer
TABLE 204: U.S. Diabetes Care Devices Market: Regulatory and Reimbursement Change Disclaimer

List of Figures

FIGURE 1: U.S. Diabetes Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: U.S. Diabetes Care Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Diabetes Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: U.S. Diabetes Care Devices Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Diabetes Clinical Workflow Economics Framework
FIGURE 11: Payer, Pharmacy Benefit and Health-System Procurement Decision Framework
FIGURE 12: Patient Lifetime Value and Recurring Consumables Economics Model
FIGURE 13: PESTEL Analysis
FIGURE 14: Porter’s Five Forces Analysis
FIGURE 15: Value Chain Analysis
FIGURE 16: Supply Chain Analysis
FIGURE 17: FDA Regulatory and Interoperability Framework
FIGURE 18: CMS and Private Payer Coverage Pathway
FIGURE 19: Connected Diabetes Care Ecosystem
FIGURE 20: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 21: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Self-Monitoring Blood Glucose Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Insulin Delivery Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Automated Insulin Delivery Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Digital and Connected Diabetes Care Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 28: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Type 1 Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Insulin-Treated Type 2 Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Non-Insulin-Treated Type 2 Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Gestational Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Inpatient and Acute-Care Glycemic Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 35: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Hospitals and Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Endocrinology and Diabetes Specialty Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Primary Care, Retail Clinics and Community Health Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Homecare Patients and Caregivers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Telehealth and Remote Diabetes Management Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 42: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Standalone and Intermittent Monitoring Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Connected and Bluetooth-Enabled Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Wearable and Minimally Invasive Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Automated and Closed-Loop Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Software-Enabled and AI-Assisted Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Procurement & Distribution Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 49: Procurement & Distribution Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Retail Pharmacy Channel Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Durable Medical Equipment and Mail-Order Channel Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Direct Institutional Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Online, E-Commerce and Direct-to-Consumer Channel Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Payer, Employer and Population-Health Contracting Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 56: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: West Region U.S. Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 58: West Region Market Share Analysis by State, 2025
FIGURE 59: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: California Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Washington Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Arizona Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Colorado Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Oregon Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Utah Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Nevada Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: New Mexico Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Idaho Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Montana Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Wyoming Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Alaska Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Hawaii Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Northeast Region U.S. Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 74: Northeast Region Market Share Analysis by State, 2025
FIGURE 75: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: New York Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Massachusetts Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Jersey Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Pennsylvania Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Connecticut Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Maine Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Vermont Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: New Hampshire Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Rhode Island Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Delaware Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: South Region U.S. Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 87: South Region Market Share Analysis by State, 2025
FIGURE 88: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Texas Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Florida Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Georgia Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: North Carolina Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Tennessee Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: South Carolina Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Alabama Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Mississippi Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Louisiana Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Arkansas Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Kentucky Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Oklahoma Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Virginia Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Maryland Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: West Virginia Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Midwest Region U.S. Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 105: Midwest Region Market Share Analysis by State, 2025
FIGURE 106: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Illinois Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Ohio Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Michigan Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Minnesota Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Indiana Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Wisconsin Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Missouri Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Iowa Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Kansas Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Nebraska Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: North Dakota Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: South Dakota Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 120: Market Share by Glucose Monitoring and Insulin Delivery Portfolio, 2025
FIGURE 121: Company Positioning Matrix
FIGURE 122: Key Player Product Portfolio and Recurring-Revenue Benchmarking
FIGURE 123: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 124: U.S. Diabetes Care Device Innovation Roadmap
FIGURE 125: Future Market Scenario Analysis, 2026–2035
FIGURE 126: Disruptive Technologies Impact Matrix
FIGURE 127: Longer-Wear and Implantable CGM Adoption Roadmap
FIGURE 128: Over-the-Counter CGM Opportunity Map
FIGURE 129: Fully Automated and Bihormonal Insulin Delivery Roadmap
FIGURE 130: Interoperable Pump-CGM-Algorithm Ecosystem Map
FIGURE 131: AI-Assisted Dosing and Glycemic Risk Prediction Roadmap
FIGURE 132: Technology Adoption Curve, 2026–2035
FIGURE 133: Strategic Growth Roadmap for U.S. Diabetes Device Companies
FIGURE 134: Payer Access and Evidence Strategy Framework
FIGURE 135: Pharmacy versus DME Go-to-Market Framework
FIGURE 136: Product Positioning and Portfolio Expansion Framework
FIGURE 137: Partnership, Interoperability and Ecosystem Strategy Framework
FIGURE 138: Commercialization Roadmap, 2026–2035
FIGURE 139: Report Scope and Disclaimer Framework